Targeted therapies in melanoma

Cancer Treatment Reviews

Volumn 32, Issue 7, 2006, Pages 524-531

  Queirolo, Paola ^a   Acquati, Mirko ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Melanoma; Monoclonal antibody; Protein kinase; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CP 675206; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IMATINIB; IPILIMUMAB; MARIMASTAT; MELAN A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; OBLIMERSEN; PACLITAXEL; PI 88; PLACEBO; PROTEIN KINASE INHIBITOR; SEMAXANIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG UTILIZATION; EARLY DIAGNOSIS; ENZYME INHIBITION; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INHIBITION KINETICS; INJECTION SITE REACTION; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MEDICAL SPECIALIST; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; NONHUMAN; PROGNOSIS; PRURITUS; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UVEITIS;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; APOPTOSIS; HUMANS; MELANOMA; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 33749063942     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.07.009     Document Type: Review

References (75)

1. Eggermont A.M.M., and Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 40 (2004) 1825-1836
2. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 (1999) 2745-2751
3. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 (2002) 2045-2052
4. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22 (2004) 1118-1125
5. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (2000) 158-166
6. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
7. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
8. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
9. Chong H., Vikis H.G., and Guan K.L. Mechanisms of regulating the Raf kinase family. Cell Signal 15 (2003) 463-469
10. Satyamoorthy K., Li G., Gerrero M.R., et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63 (2003) 756-759
11. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65 (2005) 2412-2421
12. Brose M.S., Volpe P., Feldman M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002) 6997-7000
13. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
14. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 23 (2004) 6292-6298
15. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
16. Ahmad T., Marais R., Pyle L., et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Proc Am Soc Clin Oncol 22 (2004) [abstr. 7506]
17. Flaherty K.T., Brose M., Schucter L., et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol 22 (2004) [abstr. 7507]
18. Eisen T., Ahmad T., Gore M.E., et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Proc Am Soc Clin Oncol 23 (2005) [abstr. 7508]
19. Demetri G.D., von Mehren B., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
20. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
21. Janku F., Tomancova V., Novotny J., et al. Expression of c-Kit was found in more than 50% of early stages malignant melanoma. A retrospective study of 261 patients. Proc Am Soc Clin Oncol 22 (2003) [abstr 2864]
22. Shen S.S., Zhang P.S., Eton O., and Prieto V.G. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30 (2003) 539-547
23. McGary E.C., Onn A., Mills L., et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 122 (2004) 400-405
24. Redondo P., Lloret P., Andreu J., and Inoges S. Imatinib mesylate in cutaneous melanoma. J Invest Dermatol 123 (2004) 1208-1209
25. Eton O., Billings L., Kim K., et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). Proc Am Soc Clin Oncol 22 (2004) [abstr 7528]
26. Schuchter L., Flaherty K., Davidson R., et al. Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. Proc Am Soc Clin Oncol 22 (2004) [abstr 7572]
27. Ugurel S., Hildenbrand R., Zimpfer A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92 (2005) 1398-1405
28. Meric-Bernstam F., and Mills G.B. Mammalian target of rapamycin. Semin Oncol 31 (2004) 10-17
29. Margolin K., Longmate J., Baratta T., et al. CCI-779 in metastatic melanoma. Cancer 104 (2005) 1045-1048
30. Egen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3 (2002) 611-618
31. Mokyr M.B., Kalinichenko T., Gorelik L., and Bluestone J.A. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 58 (1998) 5301-5304
32. Tchekmedyian S., Glasby J., Korman A., Keler T., Deo Y., and Davis T.A. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol 21 (2002) [abstr. 56]
33. Hersh E.M., Weber J., Powderly J., et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. Proc Am Soc Clin Oncol 22 (2004) [abstr. 7511]
34. Fischkoff S.A., Hersh E., Weber J., et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Proc Am Soc Clin Oncol 23 (2005) [abstr. 7525]
35. van Elsas A., Sutmuller R.P., Hurwitz A.A., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194 (2001) 481-489
36. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
37. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005) 741-750
38. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23 (2005) 8968-8977
39. Reuben M., Lee B.N., Li C., et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106 (2006) 2437-2444
40. Trefzer U., Kors C., Pelzer K., Walden P., Sterry W., and O'Keefe E. Preliminary results of a phase I trial of intralesional injection of CPG 7909 in patients with basal cell carcinoma or melanoma. Proc Am Soc Clin Oncol 21 (2002) [abstr. 1902]
41. Wagner S.N., Pashenkov M., Goess G., et al. TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune). Proc Am Soc Clin Oncol 22 (2004) [abstr 7513]
42. Wagner S., Weber J., Redman B., et al. CPG 7909, a TLR9 Agonist Immunomodulator in Metastatic Melanoma: A Randomized Phase II Trial Comparing Two Doses and in Combination with DTIC. Proc Am Soc Clin Oncol 23 (2005) [abstr 7526]
43. Kruit W.H., van Ojik H., Portielje J., Verloes R., Delire M., and Stoter G. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Proc Am Soc Clin Oncol 21 (2002) [abstr 1854]
44. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746
45. Kim R., Emi M., Tanabe K., and Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101 (2004) 2491-2502
46. Selzer E., Schlagbauer-Wadl H., Okamoto I., Pehamberger H., Potter R., and Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 8 (1998) 197-203
47. Klasa R.J., Gillum A.M., Klem R.E., and Frankel S.R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12 (2002) 193-213
48. Jansen B., Schlagbauer-Wadl H., Brown B.D., et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 (1998) 232-234
49. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitization of malignant melanoma Bcl-2 antisense therapy. Lancet 356 (2000) 1728-1733
50. Millward M.J., Bedikian A.Y., Conry R.M., Gore M.E., Pehamberger H.E., and Sterry W. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Proc Am Soc Clin Oncol 22 (2004) [abstr 7505]
51. Kirkwood J.M., Bedikian A.Y., Millward M.J., et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Proc Am Soc Clin Oncol 23 (2005) [abstr 7506]
52. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
53. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
54. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
55. Ugurel S., Rappl G., Tilgen W., and Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19 (2001) 577-583
56. Carson W.E., Biber J., Shah N., et al. A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proc Am Soc Clin Oncol 22 (2003) [abstr 2873]
57. Peterson A.C., Swiger S., Stadler W.M., Medved M., Karczmar G., and Gajewski T.F. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10 (2004) 4048-4054
58. Albelda S.M., Mette S.A., Elder D.E., Stewart R.M., Damjanovich S., Herlyn M., et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50 (1990) 6757-6774
59. Dome B., Raso E., Dobos J., et al. Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype. Int J Cancer 116 (2005) 27-35
60. Hersey P., Sosman J., O'Day S., et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 23 (2005) [abstr 7507]
61. Joyce J.A., Freeman C., Meyer-Morse N., et al. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24 (2005) 4037-4051
62. Tobu M., Ma Q., Iqbal O., et al. Comparative tissue factor pathway inhibitor release potential of heparins. Clin Appl Thromb Hemost 11 (2005) 37-47
63. Thomson D.B., Gonzalez R., Millward M., et al. A phase II trial of PI-88, a novel antiangiogenic and antimetastatic heparanase inhibitor, in patients with advanced melanoma. Proc Am Soc Clin Oncol 23 (2005) [abstr 7559]
64. Rajkumar S.V., Richardson P.G., Hideshima T., and Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23 (2005) 630-639
65. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumour agents. Cancer Res 59 (1999) 2615-2622
66. Amiri K.I., Horton L.W., LaFleur B.J., Sosman J.A., and Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64 (2004) 4912-4918
67. Markovic S.N., Geyer S.M., Dawkins F., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
68. Brown P.D., and Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6 (1995) 967-974
69. Ramnath N., and Creaven P.J. Matrix metalloproteinase inhibitor. Curr Oncol Rep 6 (2004) 96-102
70. Loffek S., Zigrino P., Angel P., Anwald B., Krieg T., and Mauch C. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1 alpha and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol 124 (2005) 638-643
71. Quirt I., Bodurth A., Lohmann R., et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20 (2002) 431-437
72. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16 (1998) 1752-1759
73. Atkins M.B., O'Boyle K.R., Sosman J.A., et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12 (1994) 1553-1560
74. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17 (1999) 968-975
75. Del Vecchio M., Bajetta E., Nova P., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanoma. Ann Oncol 17 (2006) 571-577